Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax.

ABSTRACT:

Background

TP53 mutation (TP53^mut ) confers an adverse prognosis in acute myeloid leukemia (AML). Venetoclax with hypomethylating agents is a current standard for older patients; however, recent reports suggest that TP53^mut confers resistance to venetoclax. The authors investigated the outcomes of patients with TP53^mut AML who were treated with a 10-day decitabine and venetoclax (DEC10-VEN) (ClinicalTrials.gov identifier NCT03404193).

Methods

Patients with newly diagnosed AML received decitabine 20 mg/m² for 10 days every 4 to 6 weeks for induction, followed by decitabine for 5 days after response. The venetoclax dose was 400 mg daily. TP53^mut was identified in bone marrow samples using next-generation sequencing, with s

SUBMITTER: Kim K 

PROVIDER: S-EPMC10462434 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature